Genetic variation in immune system may impact the severity of COVID-19

Genetic variation in immune system may impact the severity of COVID-19

Can your genes be the reason for increased susceptibility to COVID-19 infection? For years, scientists know that genes play a very important role in underlying biological mechanisms. And therefore, over these years many pieces of research have been carried to understand the link between genetic variability and diseases.  Recently, new research published in the Journal of Virology (Well-known publication of American Society for Microbiology) highlights that variation in the genes involved in the human immune system can impact the susceptibility and severity of COVID-19 infection.

Human Leukocytes Antigen Genes

You must have seen people of a certain group be more susceptible to disease than others, why? Well, the answer to this lies in your genes. Individual gene variation is known to be one of the major reasons behind the differences in the immune responses. Our immune system works with the help of multiple biomolecules. One such important component of the immune system that plays a very crucial role in determining the strength of the response is the human leukocyte antigen. The genes coding for this antigen is involved in detecting the pathogen upon invasion. The gene variation among different individuals can influence how well the immune system detects the pathogen in an individual. If a person has a weak response than a pathogen such as the Sar-CoV2 virus could easily invade making a person vulnerable to the infection.

Understanding the variation

As we all know that the number of COVID-19 cases is rising across the globe, researchers and scientist are working towards finding better solutions to curb the menace. In the present study, the author of the paper indicated the importance of understanding the variation of human leukocytes antigen (HLA), which forms a very important component of the immune system. Knowing the gene variants of HLA and their respective responses towards the condition can help identify people posing a higher risk towards the COVID-19 infection.

Antigen-Antibody complex

The researchers showed that the HLA, haplotype, and also the full genotype variation may impact the ability of an individual’s immune system to respond against Sars-CoV infection. Moreover, certain alleles can be responsible for more severe infections than others.

“This is the first study to report global distributions of HLA types and haplotypes with potential epidemiological ramifications in the setting of the current pandemic,” write the authors, from Oregon Health & Science University, Portland, and the Portland VA Research Foundation.

One of the important benefits of HLA based study is that HLA typing is quite fast and less expensive. If there is a pairing of HLA typing with that of COVID-19 tests than there can be a significant improvement in the identification of high-risk individuals. Moreover, once the vaccine against COVID-19 is available, high-risk HLA type individuals can be prioritized for the vaccination. This will help in creating herd immunity and help prevent the future spread of the disease.

Scientists Help Immune System Find Hidden Cancer Cells

Scientists Help Immune System Find Hidden Cancer Cells

Cancer is a widely studied topic in bioscience research but yet remains to be mostly unknown and difficult to treat. However, the recent developments in cancer research over the past decade have helped the scientific community to come up with effective treatment methods. But still, one of the most common problems faced in treating cancer cells is difficulty in locating them for efficient targeting. Recently, scientists from Yale University have developed a new system that can help our immune system find the hidden cancer cells and kill them. The research has been published in Journal Nature Immunology.

Why this study holds importance?

It is a known fact that there exists a number of immunotherapies for treating cancers. But these therapies have certain shortcomings as they either don’t work on all patients or are inefficient in different cancer types. The major reason behind this is the failure of these therapies in identifying the cancer cells which reduces their effectiveness. This highlights an urgent need for a more targeted approach that can help curb the menace of cancer.

The development of a new system by scientists in the present study is considered to overcome the drawbacks of the earlier immune therapies. Researchers report that upon testing the new system in mice it has shown positive response against the melanoma, triple-negative breast, and pancreatic tumors, even for those tumors which are situated at a distant location from the primary tumor.

“This is an entirely new form of immunotherapy,” said Sidi Chen, senior author.

How the new system – MAEGI works?

The researchers developed a new system to target the cancer cells which combines the viral gene therapy and CRISPR based gene-editing technology. Unlike the traditional method of searching and making edits at the DNA level by incorporation of new genes, the present system uses a much more targeted approach.

The new system named as MAEGI stands for Multiplexed Activation of Endogenous Gene as Immunotherapy. This system works by searching numerous cancer-causing genes, marking their location by mimicking GPS and subsequently intensifying the signal of these locations for precise targeting.

For instance, you can consider that the new system dresses up the tumor cells in a unique manner that can be easily identified by the immune system of our body and eventually eliminate them. For this, the cold tumors cells lacking any immune cells are converted into hot tumors cells which are packed with tons of immune cells.

“And once those cells are identified, the immune system immediately recognizes them if they show up in the future,” Chen said. The new system, in theory, should be effective against many cancer types, including those currently resistant to immunotherapy, he said.

The researchers will be further optimizing this system to make the manufacturing process easier. Once optimization is done it will be subjected to clinical trials in potential cancer patients.

No wonder that cancer is a rising menace in the present world. Though many therapies are available we still need highly effective methods to treat cancer. The development of the immunotherapy-based system has given rise to a ray of hope for a more effective and proficient treatment that not only treats primary tumor cells but also the distant ones. Let’s look forward to this new development and hope for the best outcomes in subsequent clinical trials.

Source 1

Source 2

Scientists Help Immune System Find Hidden Cancer Cells

Scientists Help Immune System Find Hidden Cancer Cells

Cancer is a widely studied topic in bioscience research but yet remains to be mostly unknown and difficult to treat. However, the recent developments in cancer research over the past decade have helped the scientific community to come up with effective treatment methods. But still, one of the most common problems faced in treating cancer cells is difficulty in locating them for efficient targeting. Recently, scientists from Yale University have developed a new system that can help our immune system find the hidden cancer cells and kill them. The research has been published in Journal Nature Immunology.

Why this study holds importance?

It is a known fact that there exists a number of immunotherapies for treating cancers. But these therapies have certain shortcomings as they either don’t work on all patients or are inefficient in different cancer types. The major reason behind this is the failure of these therapies in identifying the cancer cells which reduces their effectiveness. This highlights an urgent need for a more targeted approach that can help curb the menace of cancer.

The development of a new system by scientists in the present study is considered to overcome the drawbacks of the earlier immune therapies. Researchers report that upon testing the new system in mice it has shown positive response against the melanoma, triple-negative breast, and pancreatic tumors, even for those tumors which are situated at a distant location from the primary tumor.

“This is an entirely new form of immunotherapy,” said Sidi Chen, senior author.

How the new system – MAEGI works?

The researchers developed a new system to target the cancer cells which combines the viral gene therapy and CRISPR based gene-editing technology. Unlike the traditional method of searching and making edits at the DNA level by incorporation of new genes, the present system uses a much more targeted approach.

The new system named as MAEGI stands for Multiplexed Activation of Endogenous Gene as Immunotherapy. This system works by searching numerous cancer-causing genes, marking their location by mimicking GPS and subsequently intensifying the signal of these locations for precise targeting.

For instance, you can consider that the new system dresses up the tumor cells in a unique manner that can be easily identified by the immune system of our body and eventually eliminate them. For this, the cold tumors cells lacking any immune cells are converted into hot tumors cells which are packed with tons of immune cells.

“And once those cells are identified, the immune system immediately recognizes them if they show up in the future,” Chen said. The new system, in theory, should be effective against many cancer types, including those currently resistant to immunotherapy, he said.

The researchers will be further optimizing this system to make the manufacturing process easier. Once optimization is done it will be subjected to clinical trials in potential cancer patients.

No wonder that cancer is a rising menace in the present world. Though many therapies are available we still need highly effective methods to treat cancer. The development of the immunotherapy-based system has given rise to a ray of hope for a more effective and proficient treatment that not only treats primary tumor cells but also the distant ones. Let’s look forward to this new development and hope for the best outcomes in subsequent clinical trials.

Source 1

Source 2